Hainan Sihuan Pharmaceutical

Sihuan Pharmaceutical Holdings Group Ltd. is a leading integrated pharmaceutical and medical aesthetics group in China, originally founded as Hainan Sihuan Pharmaceutical. The company operates a dual-engine business model focusing on its medical aesthetics segment and its innovative drug platforms, Xuanzhu Biopharmaceutical and Huisheng Biopharmaceutical. Sihuan is a dominant player in the Chinese cardio-cerebral vascular (CCV) market and has expanded significantly into oncology, metabolic diseases, and aesthetics, notably as the exclusive distributor of the botulinum toxin Letybo. With comprehensive R&D, manufacturing, and marketing capabilities, the group maintains a robust pipeline of small molecules and biologics. It is currently transitioning from a traditional generic drug manufacturer to an innovation-driven biopharmaceutical powerhouse.